3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
11
Prostatic Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Carcinoma
3
Pain
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Medullary
2
Carcinoma, Hepatocellular
2
von Hippel-Lindau Disease
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenoma, Islet Cell
1
Adenocarcinoma, Follicular
1
Interventions
Radiotherapy
8
Zoledronic Acid
7
Fentanyl
7
nabiximols
6
Morphine
6
Ibandronic Acid
6
Ketamine
5
Hydromorphone
5
Analgesia
5
Acetaminophen
5
Tapentadol
4
Oxycodone
4
Acupuncture Therapy
4
alvimopan
3
Ropivacaine
3
Prednisone
3
Lidocaine
3
cabozantinib
2
Tetrodotoxin
2
Mitoxantrone
2
Gabapentin
2
Duloxetine Hydrochloride
2
Docetaxel
2
Calcium
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
strontium chloride
1
resiniferatoxin
1
oxycodone-acetaminophen
1
oxycodone naloxone combination
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Pain
×
cabozantinib
×
Clear all
NCT01522443
2018-05-23
COMET-2
Exelixis
Phase 3
Terminated
119 enrolled
21 charts
NCT01605227
2018-03-14
COMET-1
Exelixis
Phase 3
Completed
1,028 enrolled
18 charts